tradingkey.logo

Nanovibronix Inc

NAOV
4.020USD
0.000
收盘 12/24, 13:00美东报价延迟15分钟
4.06M总市值
亏损市盈率 TTM

Nanovibronix Inc

4.020
0.000

关于 Nanovibronix Inc 公司

NanoVibronix, Inc. is a medical device company focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The Company's primary products include PainShield and UroShield, which are portable devices suitable for administration at home or in any care setting. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use.

Nanovibronix Inc简介

公司代码NAOV
公司名称Nanovibronix Inc
上市日期Apr 24, 2015
CEOBesser (Doron)
员工数量15
证券类型Ordinary Share
年结日Apr 24
公司地址969 Pruitt Piace
城市TYLER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编75703
电话19142333004
网址https://nanovibronix.com/
公司代码NAOV
上市日期Apr 24, 2015
CEOBesser (Doron)

Nanovibronix Inc公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
2.00
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
2.00
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
United States
462.00K
93.52%
New Zealand
20.00K
4.05%
Europe
8.00K
1.62%
Other
4.00K
0.81%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月3日 周三
更新时间: 12月3日 周三
持股股东
股东类型
持股股东
持股股东
占比
Alpha Capital Aktiengesellschaft
0.76%
Geode Capital Management, L.L.C.
0.47%
Armistice Capital LLC
0.37%
Morgan Stanley Smith Barney LLC
0.09%
Tower Research Capital LLC
0.06%
其他
98.25%
持股股东
持股股东
占比
Alpha Capital Aktiengesellschaft
0.76%
Geode Capital Management, L.L.C.
0.47%
Armistice Capital LLC
0.37%
Morgan Stanley Smith Barney LLC
0.09%
Tower Research Capital LLC
0.06%
其他
98.25%
股东类型
持股股东
占比
Holding Company
0.76%
Investment Advisor/Hedge Fund
0.47%
Hedge Fund
0.42%
Investment Advisor
0.11%
其他
98.23%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
17
5.95K
0.68%
+2.34K
2025Q2
26
142.96K
5.53%
+80.02K
2025Q1
26
100.49K
7.64%
+70.73K
2024Q4
29
390.46K
7.75%
-206.57K
2024Q3
31
421.26K
15.22%
+83.76K
2024Q2
31
243.60K
8.84%
-214.51K
2024Q1
34
373.91K
18.23%
+170.33K
2023Q4
38
117.62K
5.71%
-262.96K
2023Q3
41
131.29K
7.90%
-1.54K
2023Q2
41
49.26K
2.96%
-111.70K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Alpha Capital Aktiengesellschaft
8.25K
0.95%
+4.93K
+148.55%
May 16, 2025
Geode Capital Management, L.L.C.
--
0%
-205.00
-100.00%
Mar 31, 2025
Armistice Capital LLC
3.99K
0.46%
+3.99K
--
Mar 31, 2025
Tower Research Capital LLC
226.00
0.03%
+124.00
+121.57%
Jun 30, 2025
The Vanguard Group, Inc.
--
0%
-274.00
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
1.37K
0.16%
+854.00
+165.50%
Jun 30, 2025
Fashek (Christopher M)
34.00
0%
--
--
May 16, 2025
SBI Securities Co., Ltd.
--
0%
--
--
Jun 30, 2025
BofA Global Research (US)
1.00
0%
--
--
Jun 30, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Aug 08, 2025
Merger
10→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
公告日期
类型
比率
Aug 08, 2025
Merger
10→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1

常见问题

Nanovibronix Inc的前五大股东是谁?

Nanovibronix Inc 的前五大股东如下:
Alpha Capital Aktiengesellschaft持有股份:8.25K,占总股份比例:0.95%。
Geode Capital Management, L.L.C.持有股份:0.00,占总股份比例:0.00%。
Armistice Capital LLC持有股份:3.99K,占总股份比例:0.46%。
Tower Research Capital LLC持有股份:226.00,占总股份比例:0.03%。
The Vanguard Group, Inc.持有股份:0.00,占总股份比例:0.00%。

Nanovibronix Inc的前三大股东类型是什么?

Nanovibronix Inc 的前三大股东类型分别是:
Alpha Capital Aktiengesellschaft
Geode Capital Management, L.L.C.
Armistice Capital LLC

有多少机构持有Nanovibronix Inc(NAOV)的股份?

截至2025Q3,共有17家机构持有Nanovibronix Inc的股份,合计持有的股份价值约为5.95K,占公司总股份的0.68%。与2025Q2相比,机构持股有所增加,增幅为-4.85%。

哪个业务部门对Nanovibronix Inc的收入贡献最大?

在FY2025Q2,--业务部门对Nanovibronix Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI